

Programme Overview

British Society for Gene and Cell Therapy Annual Conference
Technology Innovation Centre, Glasgow
9-11th June 2015



Day 1: Tuesday 9th June 2015 - Main Auditorium

09:30-15:00	BSGCT PUBLIC ENGAGEMENT DAY Technology Innovation Centre, Auditorium	
15:00	Conference registration opens – Technology Innovation Centre	
16:00-16:10	Welcome and Opening announcements by Andrew Baker, BSGCT President	
16:10-17:00	SPECIAL GUEST LECTURE: AAV at 50: A golden anniversary of discovery, research, and gene therapy success in the Samulski Lab R. Jude Samulski, UNC School of Medicine Chair: Andrew Baker, University of Glasgow	SGL01
17:00-18:00	FAIRBAIRN AWARD PRESENTATIONS	
17:00-17:15	Production of FVIII in the lungs , Kamila Pytel, Imperial College London	FB01
17:15-17:30	Intravenously administered gene therapy for the treatment of neuronopathic Gaucher Disease , Giulia Massaro, UCL School of Pharmacy, London	FB02
17:30-17:45	Conscious whole body bioluminescence in somatic-transgenic rodents can be used to quantify and predict brain damage in a mouse model of Cerebral Palsy , Rajvinder Karda, Imperial College London	FB03
17:45-18:00	Pre-clinical model of lentiviral gene therapy using autologous fibroblasts for treatment of Recessive Dystrophic Epidermolysis Bullosa , Christos Georgiadis, UCL, Institute of Child Health, London	FB04
18:00-18:15	<i>Comfort break</i>	
SYMPOSIUM 1: Clinical trials in novel therapeutics. Chairs: Uta Griesenbach, Imperial College London & Claire Booth, UCL Institute of Child Health Venue: Main Auditorium		In association with 
18:15-18:45	HIV targeting , Dale Ando, Sangamo BioSciences Inc	INV01
18:45-19:15	Evolving Gene Therapy for Primary Immunodeficiency Adrian Thrasher, University College London	INV02
19:15-19:45	Hematopoietic stem cell gene therapy , Nathalie Cartier, Inserm	INV03
19:45-21:30	<i>Civic Drinks Reception courtesy of Glasgow City Council, buffet, exhibition and posters</i>	
21:30	<i>Evening free for delegates to network and enjoy Glasgow</i>	

Day 2: Wednesday 10th June 2015

08:00	Conference desk opens – Technology Innovation Centre	
SYMPOSIUM 2: Genome/cell engineering technologies. Chairs: Chris Denning, The University of Nottingham & Rafael J. Yáñez-Muñoz, Royal Holloway-University of London Venue: Main Auditorium		In association with 
08:30-09:00	Genome Editing: From disease modeling to novel therapeutics Chad Cowan, Harvard University	INV04
09:00-09:30	Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library, Kosuke Yusa, Wellcome Trust Sanger Institute	INV05
09:30-10:00	Targeted gene editing in iPSC from disease modelling towards therapy, Toni Cathomen, University Medical Centre Freiberg	INV06
10:00-10:15	CCR5-Uco-TALEN - a novel transcription activator-like effector nuclease that mediates high-efficiency knockout of HIV co-receptor CCR5 in primary T cells after mRNA transfection Ulrike Mock, Institute of Child Health, University College London	SEL01
10:15-10:45	<i>Morning refreshments, exhibition and posters</i>	
SYMPOSIUM 3: RNA-based therapeutics. Chairs: Matthew Wood, University of Oxford & Mustafa Munye, UCL Institute of Child Health Venue: Main Auditorium		
10:45-11:15	Targeting repeat expansion diseases with duplex RNAs, David Corey, University of Texas	INV07
11:15-11:45	Genomic medicine for neuromuscular disease, Matthew Wood, University of Oxford	INV08
11:45-12:15	Splice-switching in an animal model for X-linked agammaglobulinemia and for PCSK9 modulation, C.I. Edvard Smith, Karolinska Institutet	INV09
12:15-12:30	Delivery of host targeted miRNA therapeutics for the treatment of respiratory viral infections Gerry McLachlan, University of Edinburgh	SEL02
12:30-13:30	<i>Lunch, exhibition and posters</i>	
12:30-13:30	Regulatory and clinical trial drop-in clinic. In association with Regulators and the Cell Therapy Catapult	
13:00-13:30	BSGCT ANNUAL GENERAL MEETING – BSGCT MEMBERS Auditorium	

Day 2: Wednesday 10th June 2015

SYMPOSIUM 4: Cancer.

Chairs: Len Seymour, University of Oxford &
Alan Parker, Cardiff University
Venue: Main Auditorium

In association with



13:30-14:00	Using viruses to treat cancer , Liz Ilet, University of Leeds	INV10
14:00-14:30	Adoptive T cell therapy for cancer , Dave Gilham, The University of Manchester	INV11
14:30-15:00	Engineering measles virus for cancer therapy , Guy Ungerechts, National Center for Tumor Diseases, Heidelberg	INV12
15:00-15:15	Tumour regression after intravenous administration of novel tumour-targeted nanomedicines Christine Dufes, University of Strathclyde	SEL03
15:15-15:45	<i>Afternoon refreshments, exhibition and posters</i>	

SYMPOSIUM 5: Cutting edge viral technologies.

Chairs: Hildegard Büning, University of Cologne &
Stuart Nicklin, University of Glasgow
Venue: Main Auditorium

In association with



15:45-16:15	Alpharetroviral vectors: From their retroviral biology to a potential clinical perspective , Axel Schambach, Hannover Medical School	INV13
16:15-16:45	Receptor-targeted viral vectors , Christian Buchholz, Paul-Ehrlich Institut	INV14
16:45-17:15	A single maturation cleavage site in AdV regulates cell entry and virus assembly , Glen Nemerow, The Scripps Research Institute	INV15
17:15-17:30	Novel LTR-1 lentiviral vectors are fully functional in vitro and in vivo following the removal of HIV-1 gag-RRE sequences , Steven Howe, University College London	SEL04
17:30-18:45	<i>Exhibition, drinks and poster judging</i>	

19:00

**CONFERENCE DINNER,
The Barony, Glasgow.**

After dinner speech – Len Seymour, University of Oxford

In association with



Day 3: Thursday 11th June 2015

08:30 **Conference desk opens** – Technology Innovation Centre



SYMPOSIUM 6: Clinical gene and cell therapy approaches.

Chairs: Adrian Thrasher, University College London &
Mike Paul-Smith, Imperial College London
Venue: Main Auditorium

In association with



07:45-08:45 **BSGCT Board Meeting, HQ Hotel**

Day 3: Thursday 11th June 2015			
09:00-09:25	A Phase IIb double-blind, placebo-controlled trial of non-viral mediated gene therapy for cystic fibrosis, Uta Griesenbach, Imperial College London	INV16	
09:25-09:50	Enadenotucirev is a well-tolerated group B oncolytic adenovirus that can access and infect tumour cells in cancer patients following intravenous delivery, Kerry Fisher, University of Oxford	INV17	
09:50-10:15	Human Hepatocyte Transplantation for liver based metabolic disorders and acute liver failure, Anil Dhawan, King's College London	INV18	
10:15-10:45	<i>Morning refreshments (bacon rolls), exhibition and posters</i>		
SYMPOSIUM 7: Organ regeneration/tissue engineering approaches. Chairs: Ulrich Martin, Hannover Medical School, & Sian Harding, Imperial College London <i>Venue: Main Auditorium</i>		In association with 	
10:45-11:15	Induced pluripotent stem cells: New Ways to Refurbish Old Hearts? Ulrich Martin, Hannover Medical School	INV19	
11:15-11:45	Should we be engineering cells or their environment for the future of cardiac repair? Andrea Gobin, Assistant Director of the Organ Repair & Regeneration Research group at Texas Heart Institute.	INV20	
11:45-12:30	BIRAX SPECIAL GUEST LECTURE: Human pluripotent stem cell derived pericytes, from culture vessels to vessel walls, Joseph Itskovitz-Eldor, Technion, Haifa Chair: Sian Harding, Imperial College London	 <small>The British Israel Research And Academic Exchange Partnership Regenerative Medicine Initiative</small>	SGL02
12:30-12:40	Close of Conference and award presentations, BSGCT President		
12:40-13:30	<i>Networking lunch</i>		

Regulatory and clinical trial drop-in clinic Wednesday 10th June 2015 12:30-13:30 **Break out room 3, Level 03**

There are growing numbers of cell and gene therapies progressing towards, or currently in clinical trials in the UK. Designing and conducting the supporting pre-clinical efficacy, safety and manufacturing process work as well as planning and conducting the clinical trial itself can bring challenges. This drop-in clinic is an opportunity for researchers involved in bringing cell or gene therapies into clinical trial to have an informal discussion with regulators and other experts about any aspects of preparing for or conducting clinical trials. The drop-in clinic is supported by the Cell Therapy Catapult and includes senior representatives working in this area from the MHRA, HTA and HRA.



This drop-in clinic is an opportunity for researchers involved in bringing cell or gene therapies into clinical trial to have an informal discussion with regulators and other experts about any aspects of preparing for or conducting clinical trials. The drop-in clinic is supported by the Cell Therapy Catapult and includes senior representatives working in this area from the MHRA, HTA and HRA.

Disclaimer: Speaker names, affiliations, abstract titles and abstracts in the Programme are presented as submitted by the corresponding author.